Table 3

Numbers of events (person-time) and incidence rates of infections per 100 PY standardised by age and sex* (with 95% CIs)†, in the main cohorts from five RA registries and one RA clinical trial programme

Hospitalised infectionTuberculosisHospitalised
Herpes zoster
Herpes zoster
Incidence rate of hospitalised infection per 100 PY (95% CI)*†Fostamatinib trials2.92* (2.44 to 3.46)†NCNC1.14 (0.85 to 1.49)
CORRONA1.30 (1.18 to 1.42)0.04 (0.03 to 0.06)0.02 (0.01 to 0.04)0.66 (0.59 to 0.73)
SRR1.62 (1.52 to 1.72)0.02 (0.01 to 0.03)0.01 (0.01 to 0.02)NA
NOAR1.56 (1.30 to 1.88)NCNCNA
CORRONA International1.50 (1.09 to 2.05)0.35 (0.17 to 0.67)NC0.26 (0.11 to 0.54)
IORRA1.14 (1.05 to 1.25)0.17 (0.13 to 0.22)0.15 (0.12 to 0.19)1.94 (1.82 to 2.07)
  • *Rate: incidence rates per 100 PY. Incidence rates for the registry data were standardised according to the age and sex distribution in the RA clinical trial programme overall analysis; for the RA clinical trial programme crude incidence is presented

  • †95% CI: approximate CIs based on the gamma distribution for registry data and exact Poisson CIs for the RA clinical trial programme.

  • CORRONA, Consortium of Rheumatology Researchers of North America; IORRA, Institute of Rheumatology Rheumatoid Arthritis; NA, not available; NC, not calculated due to too few events (rates were only produced if at least five events were observed); NOAR, Norfolk Arthritis Register; PY, person-years; SRR, Swedish Rheumatology Quality of Care Register.